This paper explores several approaches to drug development and their application in rare diseases. In particular, it focuses on the pros and cons of the “Constellation” approach, which can be used to study a therapy’s impact on multiple disease states in parallel, potentially resulting in shorter development timelines, approval in multiple diseases, and a higher asset value.
